Tested. Trusted.

Tru-D SmartUVC.

The results are in for the first-ever randomized clinical trial on UVC disinfection. The Benefits of Enhanced Terminal Room Disinfection (BETR-D) study was funded by the Centers for Disease Control and Prevention (CDC) and conducted across nine hospitals in the Duke Infection Control Outreach Network (DICON)  from 2012-2014.

Click to view the Duke Video

Click to view the UNC Video

Tru-D’s patented Sensor360® technology, which measures the reflected UVC dose,
is proven to reduce the risk of acquisition and infection caused by epidemiologically-important pathogens among patients admitted to the same room by a cumulative 30%.

The BETR-D Study

9 Hospitals, 25k Disinfection Cycles, 600k+ Room Stays
$2M CDC-funded randomized clinical trial

The BETR-D Study

Designed to examine the impact of enhanced terminal room disinfection as a method to prevent HAIs, the BETR-D Study, the most comprehensive study on UV disinfection to date, was a cluster randomized, multicenter crossover study with 2x2 factorial design to evaluate the impact of enhanced terminal room disinfection on acquisition and infection caused by multidrug-resistant organisms (MDROs).

Duke Infection Control Outreach Network

Assisting hospitals with limited resources to develop cutting-edge infection control programs

Duke Infection Control Outreach Network

The DICON exists to help hospitals with limited resources developed cutting-edge infection control programs and to give institutions with more sophisticated programs access to comparative statistics to support their infection control efforts.

CDC's Prevention Epicenters Program

Working directly with academic partners to address important scientific questions

CDC's Prevention Epicenters Program

The CDC's Prevention Epicenter Program program was created in 1997 to enhance preventability of health care-associated infections (HAIs). The program works directly with academic partners to address important scientific questions regarding the prevention of HAIs, antibiotic resistance and other adverse events associated with health care.

Results

Reduced Risk of Acquisition from Patient to Patient and Facility-wide

Results

The BETR-D study proves that enhanced terminal room disinfection strategies using Tru-D decreased the risk of clinical incidence of target MDROs among patients admitted to the same room by 30 percent.

How did the BETR-D study come about?

Leading researchers in infection prevention and control wanted to conduct a randomized clinical trial that would determine the efficacy, effectiveness and feasibility of enhanced terminal room disinfection to prevent hospital-acquired infections.

What was the impact hospital-wide?

This secondary analysis of the BETR-D study proves that with an enhanced terminal room UV disinfection program in place, the entire hospital environment is safer. Regardless of whether the room was previously occupied with a patient who had an MDRO (multidrug-resistant organism), or whether or not they had been previously colonized, if you add a structured, targeted UV disinfection program to your cleaning protocols, your hospital will have fewer cases of C. diff and VRE.